Journal of Clinical Oncology
Articles in this Issue
Outcomes of therapy-related AML (T-AML) with venetoclax-based therapies.
6549 Background: T-AML refers to AML in patients (pts) with prior exposure to cytotoxic chemotherapy (CT) and/or radiotherapy (RT) and is often associated...
Efficacy and safety of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone for previously untreated diffuse large B-cell lymphoma: A real-world, multi-center, retrospective cohort study.
7061 Background: In the POLARIX study, Pola-R-CHP showed significant improvement in progression free survival (PFS) in pre...
Identification and validation of hypoxia and energy metabolism-related gene signatures in lung adenocarcinoma and their potential implications for immunotherapy.
e20587 Background: Lung cancer is the leading cause of cancer-related deaths globally, with non-small cell lung cancer (NSCLC) constituting a majority of...
Cytokine release syndrome among acute lymphocytic leukemia adults undergoing treatment with blinatumomab in the United States.
e18518 Background: Blinatumomab is a bispecific antibody that works as a T-cell engager and can trigger CD3-positive T cells to attack CD19-positive B cel...
Single-incision laparoscopic surgery vs conventional laparoscopic surgery for colorectal cancer: Short-term outcomes of a multi-center, randomized, controlled trial.
3589 Background: Single-incision laparoscopic surgery (SILS) is increasingly being embraced in the medical community due to its potential to offer less-in...
Board certification practices of US hematologists and oncologists.
9034 Background: United States (US) fellowship programs train physicians in both hematology and medical oncology (HO), yet fellows often focus on only one...
Induction chemotherapy followed by chemoradiotherapy with cisplatin or cetuximab for unresectable locally advanced head and neck cancer (TTCC-2007-01 trial): Analysis of genomic biomarkers by next-generation sequencing after long-term outcomes.
6054 Background: Induction chemotherapy (ICT) may provide survival benefit in some patients (pts) with unresectable locally advanced squamous head and nec...
Obesity, chemotherapy dosing, and toxicity: Results from the Optimal Breast Cancer Chemotherapy Dosing study.
547 Background: ASCO guidelines state that most cytotoxic drugs should be dosed according to full body surface area (BSA) without limiting the dose on the...
Moving beyond the traditional two-step approach for prognosis prediction: The BayeSarc model.
11572 Background: Extremity Soft tissue sarcomas (eSTS) are rare and heterogeneous, limiting the collection of large datasets for robust predictive modeli...
Gene expression profiling of the tumor microenvironment in Asian American and Native Hawaiian/Pacific Islander women with triple negative breast cancer.
e12622 Background: Triple negative breast cancer (TNBC) accounts for approximately 10-20% of breast cancer cases and has the worst overall survival and pr...
Hospital outcomes in patients with neuroendocrine tumors and atrial-fibrillation/flutter.
e23066 Background: Neuroendocrine Tumors (NETs) are rare, aggressive malignancies that often metastasize widely and can cause significant complications, i...
Assessment of the availability of radiotherapy services across Nigeria.
e13572 Background: Radiotherapy is an important treatment mode in managing cancers, more so in Africa and Nigeria in particular, where most patients with...
Global trends in disability-adjusted life years (DALYs) and mortality rates of pancreatic cancer in adults aged 70 and older: A Global Burden of Disease analysis (1990–2021).
e16426 Background: Pancreatic cancer (PC) represents a growing global health challenge, particularly among adults aged 70 and older, whose burden has yet...
Global and regional burden of high BMI-related pancreatic cancer from 1990 to 2021: An analysis of GBD study 2021.
e16431 Background: Obesity and overweight represent a significant concern for public health, with recent statistics showing that approximately two thirds...
Pembrolizumab plus lenvatinib in women with advanced or recurrent uterine carcinosarcoma.
e17625 Background: Uterine carcinosarcoma (UCS) though rare, accounting for 5% of all uterine cancers, is responsible for more than 16% of all deaths caus...
Preclinical evaluation of the efficacy of anti-PVR antibody-drug conjugates combined with anti-PD-1 therapy for bladder cancer.
e16547 Background: Poliovirus receptor (PVR) is a ligand for TIGIT and plays a crucial role in tumor immune evasion. We have identified that PVR is highly...
Pharmacotherapy as an adjunct to behavioral weight loss treatment in survivors of breast cancer.
11039 Background: Approximately half of breast cancer (BC) survivors attain 5% weight loss with 6 months of behavioral intervention alone. We conducted a...
Incidence of ocular toxicities in patients with relapsed/refractory multiple myeloma treated with belantamab mafodotin: A systematic review and meta-analysis of phase 3 randomized controlled trials.
12040 Background: Belantamab mafodotin is a novel antibody-drug conjugate approved by the FDA in August 2020 to treat relapsed/refractory multiple myeloma...
Comparative efficacy of cabozantinib or lenvatinib following atezolizumab plus bevacizumzb in patients with advanced hepatocellular cancer.
4123 Background: Atezolizumab plus bevacizumab is the most commonly utilized first-line therapy for advanced HCC. However, the optimal choice for second-l...
At-risk cancer genetic syndrome identification (ARCAGEN-ID): Novel EHR integrated system to overcome disparities in identification and testing for cancer genetic syndromes.
1600 Background: Identifying individuals at-risk for a hereditary cancer syndrome (HCS) is crucial to prevent cancer deaths. While there are established g...
Complete blood count as a prognostic tool for NSCLC patients treated with immune checkpoint inhibitors.
e20564 Background: Lung cancer accounts for 1.8 million deaths annually, making it the leading cause of cancer-related mortality, with 85% of cases diagno...
Tracking circulating tumor DNA through liquid biopsy after radiotherapy for dynamic risk monitoring in cancer patients.
6053 Background: Circulating tumor DNA (ctDNA) analysis provides a useful tool for non-invasive tumor burden assessment. However, the management of detect...
Safety of angiotensin converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) in patients with bladder and upper tract malignancies undergoing platinum-based chemotherapy: A retrospective study.
e16563 Background: ACEis and ARBs are commonly used in the management of hypertension and cardiovascular disease, but little is known about their safety a...
Evaluating quality of life improvements in radiation cystitis and head and neck cancer patients following hyperbaric oxygen therapy.
e24043 Background: Radiation therapy remains a critical modality in the treatment of various cancers, but it often leads to adverse effects in surrounding...
Impact of chemotherapy on financial toxicity in African-American breast cancer patients: Early findings from the navigator-assisted hypofractionation (NAVAH) phase I clinical trial.
518 Background: With the rising cost of chemotherapy, the financial toxicity (FT) of systemic therapy can substantially impair patient quality of life. FT...